Friedrich-Schiller-Universitaet Jena — Clinical Trial Site

9 Registered trials

4 Currently recruiting

Organisation

Friedrich-Schiller-Universitaet Jena

Location

Jena, Germany

Identifier

ORG-100025450

Address

Am Klinikum 1, Lobeda, 07747, Germany

Departments

Cystic Fibrosis Center
Department of Anesthesiology and Intensive Care Medicine
Department of Otorhinolaryngologyspartment of
KIM II Hämatologie und Intern. Onkologie
Klinik fur Frauenheilkunde und Geburtshilfe
Klinik für Herz- und Thoraxchirurgie
Klinik für Innere Medizin II
Klinik für Innere Medizin II Abteilung Hämatologie und internistische Onkologie
Klinik für Kinder- und Jugendmedizin

Clinical trials at this site (9)

Search interface

A 52 week study in which neither Sponsor or participant know the treatment assigned to subjects to compare the experimental drug (CHF 5993) … Pending

2024-514248-95-00 Uncontrolled Asthma 5
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke… Pending

2024-514682-19-00 Resected pancreatic ductal adenocarcinoma 5
Multicenter, Open-Label, Randomized Study of Nipocalimab or IVIG in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (F… Recruiting

2023-509434-19-00 Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) 5 2025-02-10
Reduction of occurence of Acute Kidney Injury through administration of angiotensin II versus Noradrenaline Recruiting

2024-517771-21-00 Acute kidney injury 11 2025-03-31
Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with… Recruiting

2024-515924-35-00 New-Onset Post-Operative Atrial Fibrillation after CABG 6 2023-01-16
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Recruiting

2022-500783-35-00 Acute Myeloid Leukemia 5 2022-12-06
This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Pat… Ended

2023-507338-26-00 Histologically documented gastric or gastroesophageal j 5 2021-02-01
ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty… Ended

2024-513947-94-00 locally advanced (stage III) and not suitable for curat 4 2020-03-30
Safety, tolerability, and efficacy of ACOU085 for prevention of hearing loss in testicular cancer patients receiving cisplatin Ended

2023-503696-15-00 sensorineural hearing loss (SNHL) 4 2023-11-10